Italy's "Welpharma" model for retraining

23 March 2009

Italy's research-based pharmaceutical industry association, the Farmindustria, has held talks with several labor union organizations,  the Filcem-CGIL, the CISL and the Femca-Uil-Uilcem, to monitor progress  on a program set up to deal with an estimated 6,000 redundancies in the  country's drug sector since late 2007.

The "Welpharma" scheme is modelled on welfare to work initiatives and  provides for public funds to be made available to drugmakers who  train, re-train and re-employ the long-term unemployed. The program is  operated by the collaboration of the private sector, labor unions and  the Ministry of Welfare. Farmindustria said: "to exit from this crisis  is possible with innovative ideas, proposals and choices," as well as  the convergence of the full commitment of individuals and both public  and private institutions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight